Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 649
Special Issue Editor
Special Issue Information
Dear Colleagues,
Patient-derived mouse models of cancer have revolutionized cancer research over the past 50 years. Thirty years ago, we developed the patient-derived orthotopic xenograft (PDOX) model which, for the first time, enabled the tumor to behave in the mouse as it did in the patient—in particular, with regard to metastasis. The PDOX model, which has been established for all major tumor types, is now being used for drug discovery as well as individualized patient therapy. The model is particularly significant because the tumor is growing within its natural tumor microenvironment, rather than subcutaneously. Therefore, we are arranging a Special Issue of Cells which will feature the PDOX model. We welcome submissions regarding any type of PDOX model and its use in drug discovery, individualized patient therapy, molecular biology studies of tumor growth, studies on the interaction between cancer cells and stromal cells within the tumor, as well as on new imaging techniques and other emerging techniques that can help us to better understand tumor growth and how to inhibit or eradicate tumors.
I would like to invite you to write an article on the topic Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer for the Special Issue of Cells, and look forward to receiving your submission.
Prof. Robert M. Hoffman
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PDOX
- mouse models
- individualized therapy
- cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
